達安基因(002030.SZ):潤虹醫藥擬向全國股轉系統申請終止掛牌
格隆匯 3 月 19日丨達安基因(002030.SZ)公佈,2021年3月19日,公司第七屆董事會2021年第三次臨時會議審議通過了《關於參股孫公司廣州潤虹醫藥科技股份有限公司擬申請公司股票在全國中小企業股份轉讓系統終止掛牌的預案》。公司參股孫公司廣州潤虹醫藥科技股份有限公司(“潤虹醫藥”)根據戰略發展規劃及經營發展的需要,為提高運營效率、節約運營成本,擬向全國中小企業股份轉讓系統申請終止掛牌。上述事項尚須提交公司2021年第三次臨時股東大會審議批准。
潤虹醫藥公司是一家主要從事創傷修復領域醫用生物敷料的研發、生產和銷售的高新技術企業。自成立以來公司立足華南,面向全國,深耕創傷修復領域,打造創傷護理治療專家企業。潤虹醫藥主營業務與公司不存在同業競爭情況,也不屬於上市公司核心業務。潤虹醫藥向全國中小企業股份轉讓系統申請終止掛牌,不影響上市公司業務的正常開展,不影響上市公司的地位和持續盈利能力,符合公司長遠發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.